Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
NeoGenomics ( (NEO) ) has shared an announcement.
On May 22, 2025, NeoGenomics, Inc. held its annual stockholders meeting where several key proposals were approved. These included an amendment to the 2023 Equity Incentive Plan, which increased the number of shares authorized for issuance and established a minimum vesting period, among other changes. Additionally, the election of nine directors to the Board and the approval of executive compensation were confirmed. The stockholders also ratified the appointment of Deloitte & Touche LLP as the independent registered public accountant.
The most recent analyst rating on (NEO) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on NeoGenomics stock, see the NEO Stock Forecast page.
Spark’s Take on NEO Stock
According to Spark, TipRanks’ AI Analyst, NEO is a Neutral.
NeoGenomics presents a mixed investment outlook. The company shows strong revenue growth and strategic initiatives, but faces challenges with profitability, high leverage, and negative cash flow. Technical indicators suggest bearish momentum, while the valuation metrics highlight ongoing losses. Corporate leadership changes and strategic acquisitions provide some positive momentum, but investors should be cautious due to the current financial and market conditions.
To see Spark’s full report on NEO stock, click here.
More about NeoGenomics
Average Trading Volume: 2,135,197
Technical Sentiment Signal: Sell
Current Market Cap: $953.6M
For a thorough assessment of NEO stock, go to TipRanks’ Stock Analysis page.